The primary objective of Part A of this study is to investigate the safety and tolerability of AMG 732 after single subcutaneous (SC) doses. The primary objective of Part B of this study is to investigate the efficacy of AMG 732 in participants with Thyroid Eye Disease (TED) after multiple SC doses.
The primary objective of Part A of this study is to investigate the safety and tolerability of AMG 732 after single subcutaneous (SC) doses. The primary objective of Part B of this study is to investigate the efficacy of AMG 732 in participants with Thyroid Eye Disease (TED) after multiple SC doses.
A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease
-
Levenson Eye Associates, Jacksonville, Florida, United States, 32204
Ilumina Medical Research, Kissimmee, Florida, United States, 34744
Ppd Las Vegas Research Unit, Las Vegas, Nevada, United States, 89113
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to 65 Years
ALL
Yes
Amgen,
MD, STUDY_DIRECTOR, Amgen
2027-08-13